Guardant Health (GH) Cash & Equivalents (2017 - 2026)

Guardant Health has disclosed Cash & Equivalents across 10 years of filings, most recently posting $989.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $989.3 million, up 41.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $989.3 million (up 41.62% YoY), and the FY2025 annual result was $378.2 million, down 28.04% from the prior year.
• Cash & Equivalents came in at $989.3 million for Q1 2026 at Guardant Health, up from $378.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q4 2023 to a low of $141.6 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $573.6 million (2022), against an average of $560.2 million.
• Across the five-year window, Cash & Equivalents slumped 80.98% in 2022 and surged 700.25% in 2023, its largest moves.
• Guardant Health's Cash & Equivalents stood at $141.6 million in 2022, then jumped by 700.25% to $1.1 billion in 2023, then plunged by 53.64% to $525.5 million in 2024, then slipped by 28.04% to $378.2 million in 2025, then jumped by 161.58% to $989.3 million in 2026.
• The last three Cash & Equivalents figures came in at $989.3 million (Q1 2026), $378.2 million (Q4 2025), and $580.0 million (Q3 2025), per Business Quant data.